2025 Business Performance Review & 2026 Growth Strategy

2025 Performance Review & 2026 Growth Agenda

Demonstrating Revenue Ownership, Strategic Account Depth & Scalable Growth Readiness

Dipti Sharma

Business Growth & Strategic Partnerships

2025 Executive Summary

Delivered ₹5.02 Cr in total revenue through 27 strategic deals (20 New | 7 Renewals).

Created a robust ₹20.57 Cr opportunity funnel via 126 proposals and 380 meetings.

Onboarded 13 strategic brands across key therapy areas including Vaccines, Chrome, and Derma.

Successfully transitioned from transactional selling to long-term strategic partnering.

Operational Activity 2025: Monthly Meetings Analysis

Consistent engagement throughout the year resulted in 380 total meetings. Peaks in February (49) and July (38) correlate with key proposal submission windows.

Key Financial Metrics & Outcomes

Total Revenue Delivered

₹5.02 Cr

Opportunity Funnel

₹20.57 Cr

Meeting Efficiency

39% Self-Scheduled

Conversion Rigor

126 Proposals

Transformation: Selling to Partnering

Positioned CLIRNET as a long-term strategic partner rather than a vendor. We executed 500+ omnichannel touchpoints and secured Enterprise MSAs with major accounts like Bayer and Danone.

10+ Differentiated engagement concepts proposed.

Balanced mix of new client acquisition and brand renewals.

2026 Priority Accounts & Brand Focus (Q1)

<strong>GSK:</strong> Scale engagement across Augmentin, Calpol, and specialty portfolio.

<strong>Cipla:</strong> Deepen respiratory leadership positioning (Foracort, Duolin).

<strong>USV:</strong> Expand wallet share in Diabetes (Glycomet GP) and Cardiology.

<strong>Bayer:</strong> Broaden collaborations in CV, women's health, and consumer health.

<strong>Danone:</strong> Build education-led programs for Nutricia and clinical nutrition.

Strategic Innovation: Therapy Intelligence Hub™

Moving from short-term campaigns to an always-on therapy authority model.

Continuous clinical influence rather than sporadic touchpoints.

Measurable confidence shifts and predictable outcomes for partners.

Scalable framework across enterprise pharma partners.

2026 Growth Ambition: Revenue Scale Up

Targeting a ~2x increase in owned revenue responsibility, driven by multi-brand enterprise partnerships and the new Therapy Intelligence Hub model.

Leadership Progression & Team Scale Plan

<strong>Leadership Readiness:</strong> Prepared for promotion and enhanced appraisal based on demonstrated revenue ownership.

<strong>Transition:</strong> Shifting into people leadership while retaining direct revenue accountability.

<strong>Q1 2026:</strong> Onboard 1st team member under direct leadership.

<strong>Post-Q1:</strong> Expand team capacity with 2nd member to support scalability.

Building a Sustainable & Scalable Growth Engine for CLIRNET

2026 Success Vision

₹10 Cr Revenue | Deep Enterprise Partnerships | High-Performing Team